A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure

BACKGROUND: Chronic kidney disease (CKD) patients with and without heart failure (HF) often present with hyperkalaemia (HK) leading to increased risk of hospitalisations, cardiovascular related events and cardiovascular-related mortality. Renin–angiotensin–aldosterone system inhibitor (RAASi) therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, Thomas, Lewis, Ruth D., Brown, Tray, Baxter, Garth, de Arellano, Antonio Ramirez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995261/
https://www.ncbi.nlm.nih.gov/pubmed/36890464
http://dx.doi.org/10.1186/s12882-023-03088-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995261/
https://www.ncbi.nlm.nih.gov/pubmed/36890464
http://dx.doi.org/10.1186/s12882-023-03088-3

Ejemplares similares